Altimmune develops pemvidutide, an investigational peptide treatment for serious liver diseases such as MASH. ALT reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 23 | Evercore ISI Group | Maintained | Buy | |
| Jun 22 | Leerink Partners | Initiated | Buy | |
| May 18 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How ALT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in ALT in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALT is in one of them and how their past ALT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALT in an article yet. Here's the latest on the wider market.
About Altimmune
Altimmune is a biopharmaceutical company based in Gaithersburg, Maryland, that develops treatments for serious liver diseases. Its lead product candidate, pemvidutide, is an investigational peptide designed to act on both glucagon and GLP-1 receptors. The company is studying pemvidutide for steatohepatitis, a form of fatty liver disease, as well as for alcohol use disorder and liver disease caused by alcohol. Its target patients are people living with these conditions, and the drug is not yet approved for sale.
- Headquarters
- Gaithersburg, MD